Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
PROTHENA CORP PUBLIC LTD CO | Chief Development Officer | Stock Option (Right to Buy) | 50K | Feb 23, 2022 | Direct | ||
Terns Pharmaceuticals, Inc. | Director | Stock Option (Right to Buy) | 4.68K | Jul 1, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
TERN | Terns Pharmaceuticals, Inc. | Jul 1, 2024 | 1 | $0 | 4 | Jul 2, 2024 | Director |
TERN | Terns Pharmaceuticals, Inc. | Jun 10, 2024 | 1 | $0 | 4 | Jun 14, 2024 | Director |
TERN | Terns Pharmaceuticals, Inc. | Jun 12, 2023 | 1 | $0 | 4 | Jun 14, 2023 | Director |
TERN | Terns Pharmaceuticals, Inc. | Jul 26, 2022 | 1 | $0 | 4 | Jul 28, 2022 | Director |
TERN | Terns Pharmaceuticals, Inc. | Jul 26, 2022 | 0 | $0 | 3 | Jul 28, 2022 | Director |
PRTA | PROTHENA CORP PUBLIC LTD CO | Feb 23, 2022 | 1 | $0 | 4 | Feb 25, 2022 | Chief Development Officer |